UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of (S)‑1-(1-(Imidazo[1,2‑a]pyridin-6-yl)ethyl)-6-(1-methyl‑1H‑pyrazol-4-yl)‑1H‑[1,2,3]triazolo[4,5‑b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Journal of medicinal chemistry, 2014-09, Vol.57 (18), p.7577-7589

2014

Volltextzugriff (PDF)

Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies

Frontiers in pharmacology, 2024-06, Vol.15, p.1392209

2024

Volltextzugriff (PDF)

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors

Haematologica (Roma), 2024-01

2024

Volltextzugriff (PDF)

Pd-Catalyzed Alkyl to Aryl Migration and Cyclization: An Efficient Synthesis of Fused Polycycles via Multiple C−H Activation

Journal of the American Chemical Society, 2004-06, Vol.126 (24), p.7460-7461

2004

Volltextzugriff (PDF)

Synthesis of 3,4-Disubstituted Isoquinolines via Palladium-Catalyzed Cross-Coupling of 2-(1-Alkynyl)benzaldimines and Organic Halides

Journal of organic chemistry, 2003-02, Vol.68 (3), p.920-928

2003

Volltextzugriff (PDF)

Synthesis of 3-Substituted 4-Aroylisoquinolines via Pd-Catalyzed Carbonylative Cyclization of 2-(1-Alkynyl)benzaldimines

Journal of organic chemistry, 2002-10, Vol.67 (20), p.7042-7047

2002

Volltextzugriff (PDF)

Synthesis of 3,4-Disubstituted Isoquinolines via Palladium-Catalyzed Cross-Coupling of o-(1-Alkynyl)benzaldimines and Organic Halides

Organic letters, 2001-12, Vol.3 (25), p.4035-4038

2001

Volltextzugriff (PDF)

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor

Pharmacology research & perspectives, 2020-02, Vol.8 (1), p.e00559-n/a

2020

Volltextzugriff (PDF)

Synthesis of 3-Substituted 4-Aroylisoquinolines via Pd-Catalyzed Carbonylative Cyclization of o-(1-Alkynyl)benzaldimines

Organic letters, 2002-01, Vol.4 (2), p.193-196

2002

Volltextzugriff (PDF)

Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor

The Journal of pharmacology and experimental therapeutics, 2024-01, Vol.388 (1), p.156-170

2024

Volltextzugriff (PDF)

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ–PI3Kδ Dual Inhibitors

Journal of medicinal chemistry, 2019-05, Vol.62 (10), p.4936-4948

2019

Volltextzugriff (PDF)

Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers

ACS medicinal chemistry letters, 2024-05, Vol.15 (5), p.595-601

2024

Volltextzugriff (PDF)

Abstract 1931: Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS- driven cancer cells

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1931-1931

2024

Volltextzugriff (PDF)

Discovery of ( S )-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Journal of medicinal chemistry, 2014-09, Vol.57 (18), p.7577-7589

2014

Volltextzugriff (PDF)

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Blood, 2018-11, Vol.132 (Supplement 1), p.5324-5324

2018

Volltextzugriff (PDF)

Abstract 543: Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.543-543

2023

Volltextzugriff (PDF)

HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo

Blood, 2016-12, Vol.128 (22), p.3970-3970

2016

Volltextzugriff (PDF)

Abstract 4020: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4020-4020

2023

Volltextzugriff (PDF)

Abstract 6321: HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.6321-6321

2023

Volltextzugriff (PDF)

Abstract 3371: Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3371-3371

2013

Volltextzugriff (PDF)

Abstract 971: Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.971-971

2013

Volltextzugriff (PDF)

Bifunctional inhibition of HIV-1 reverse transcriptase: A first step in designing a bifunctional triphosphate

Bioorganic & medicinal chemistry letters, 2013-03, Vol.23 (5), p.1511-1518

2013

Volltextzugriff (PDF)

Abstract 3612: A novel and selective c-Met inhibitor against subcutaneous xenograft and othotopic brain tumor models

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3612-3612

2011

Volltextzugriff (PDF)

New palladium-catalyzed approaches to heterocycles and carbocycles

Dai, Guangxiu

2003

Volltextzugriff (PDF)

SYNTHESIS OF NOVEL DERIVATIVES OF 2-CYANO-3-METHYLTHIO-3′-BENZYLAMINO ACRYLATES(ACRYLAMIDES) AND THEIR BIOLOGICAL ACTIVITY

Phosphorus, sulfur, and silicon and the related elements, 1999-05, Vol.148 (1), p.235-241

1999

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(57)

Publikationsform

Sprache

Englisch
(64)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Discovery of (S)‑1-(1-(Imidazo[1,2‑a]pyridin-6-yl)ethyl)-6-(1-methyl‑1H‑pyrazol-4-yl)‑1H‑[1,2,3]triazolo[4,5‑b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors

Pd-Catalyzed Alkyl to Aryl Migration and Cyclization: An Efficient Synthesis of Fused Polycycles via Multiple C−H Activation

Synthesis of 3,4-Disubstituted Isoquinolines via Palladium-Catalyzed Cross-Coupling of 2-(1-Alkynyl)benzaldimines and Organic Halides

Synthesis of 3-Substituted 4-Aroylisoquinolines via Pd-Catalyzed Carbonylative Cyclization of 2-(1-Alkynyl)benzaldimines

Synthesis of 3,4-Disubstituted Isoquinolines via Palladium-Catalyzed Cross-Coupling of o-(1-Alkynyl)benzaldimines and Organic Halides

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor

Synthesis of 3-Substituted 4-Aroylisoquinolines via Pd-Catalyzed Carbonylative Cyclization of o-(1-Alkynyl)benzaldimines

Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ–PI3Kδ Dual Inhibitors

Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers

Abstract 1931: Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS- driven cancer cells

Discovery of ( S )-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Abstract 543: Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2

HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo

Abstract 4020: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies

Abstract 6321: HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models

Abstract 3371: Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor

Abstract 971: Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification

Bifunctional inhibition of HIV-1 reverse transcriptase: A first step in designing a bifunctional triphosphate

Abstract 3612: A novel and selective c-Met inhibitor against subcutaneous xenograft and othotopic brain tumor models

New palladium-catalyzed approaches to heterocycles and carbocycles

SYNTHESIS OF NOVEL DERIVATIVES OF 2-CYANO-3-METHYLTHIO-3′-BENZYLAMINO ACRYLATES(ACRYLAMIDES) AND THEIR BIOLOGICAL ACTIVITY

Suchergebnisse filtern